OpenAI researcher Wang Miles in talks to launch AI drug discovery startup valued at $2B
Decision Brief
What changedOpenAI researcher Wang Miles is in talks to found a $2 billion AI drug discovery startup.
Why it mattersThis signals strong investor interest in AI for life sciences, potentially reshaping biotech R&D and capital flows.
Who should careAll AI builders
Affected stackOpenAI
Source confidenceMedium · Reliable media or first-hand reporting
OpenAI researcher Wang Miles is in negotiations to launch an AI-focused drug discovery startup with a valuation of $2 billion. The funding discussions reflect growing investor appetite for leveraging AI to achieve breakthroughs in life sciences. For researchers and biotech companies in AI drug discovery, this news indicates that AI applications in drug development are attracting significant capital, which could accelerate the development of new therapies and alter the industry landscape.
Summary basis: official / RSS sourceCompiled from the source scope noted above; the original remains authoritative.
Sources
- TechCrunch：AI
Startup, funding, product, and platform AI news with fast Silicon Valley coverage.
- TechCrunch：AI
留言
登入后即可留言，和其他 builder 交换实测心得。
还没有留言，抢头香。